ciprofloxacin has been researched along with Amyotrophic Lateral Sclerosis in 2 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 7.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers." | 5.69 | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 3.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salomon-Zimri, S | 1 |
| Pushett, A | 2 |
| Russek-Blum, N | 2 |
| Van Eijk, RPA | 1 |
| Birman, N | 1 |
| Abramovich, B | 1 |
| Eitan, E | 1 |
| Elgrart, K | 1 |
| Beaulieu, D | 1 |
| Ennist, DL | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, JM | 2 |
| Drory, VE | 1 |
| Goldshtein, H | 1 |
| Muhire, A | 1 |
| Petel Légaré, V | 1 |
| Rotkopf, R | 1 |
| Peterson, RT | 1 |
| Armstrong, GAB | 1 |
1 trial available for ciprofloxacin and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; | 2023 |
1 other study available for ciprofloxacin and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Celecoxib; Ciprofloxacin; Dis | 2020 |